Hepatitis C Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who meet the standard requirements for a kidney transplant at the participating hospital or centre.
- People who are able to understand the study information and agree to take part by giving informed consent.
- People who are 18 years of age or older.
Who may not be able to join:
- People who have an active hepatitis C virus (HCV) infection that is detectable in their blood at the time of screening.
- People who have cirrhosis (severe liver scarring) or advanced liver fibrosis (significant liver scarring).
- People whose liver enzyme levels (specific blood markers called AST or ALT) are more than 2.5 times higher than the normal upper limit, based on a blood test taken within the 60 days before screening.
- People who have HIV (human immunodeficiency virus) infection, or an active hepatitis B (HBV) infection.
- People who are taking a medication that cannot be safely stopped or swapped out, if that medication is known to interact badly with the study drug.
- People who have past or current health conditions that could increase the risks of being in the study, make it difficult to follow the study requirements, or affect the reliability of the study results (confirm with trial site).
- People who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christine Durand, MD, Johns Hopkins University
Phone: 410-955-5684
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite event of HCV-related or HCV treatment-related death, fibrosing cholestatic hepatitis, or HCV relapse; Number of participants with liver injury
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.